Recent Advances and Future Directions in Lung Cancer — With Dr Ibiayi Dagogo-Jack and Stephen Liu (Proceedings from a Symposium in Partnership with NCOA and SCOS)
Lung Cancer Update
00:00
Is Ami Vantanib a Better Choice?
In terms of Exxon20, IBI says that she tends to favor Ami Vantanib. And in my own experience, I think mobile certainly does have some toxicity. But if you look at the duration of response, it was like a year and a half. Regionally, I think there's big differences. And I feel like Northeast, Mid-Atlantic, there's a lot more Ami. For me, I involve the patient. If travel is a big issue, Ithink mobile maybe has a leg up. Overall, I tend to use more Ami than Osamurtnib.
Transcript
Play full episode
